First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease

Introduction: The effect of local ablative therapy (LAT) for oligoprogressive epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) remains undetermined. This study aimed to investigate the survival benefit of addition of LAT to EGFR-TKIs in EGFR-mutant NSCLC patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Qinghua, Liu, Hui, Meng, Shuyan, Jiang, Tao, Li, Xuefei, Liang, Shixiong, Ren, Shengxiang, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360299/
https://www.ncbi.nlm.nih.gov/pubmed/30719148
http://dx.doi.org/10.7150/jca.26494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360299/
https://www.ncbi.nlm.nih.gov/pubmed/30719148
http://dx.doi.org/10.7150/jca.26494

Ejemplares similares